Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan

RATIONALE & OBJECTIVE: The impact of tolvaptan on health-related quality-of-life (HRQoL) in patients with autosomal dominant polycystic kidney disease (ADPKD) is unknown. To address this knowledge gap, we studied patient-reported HRQoL in patients enrolled in the Bern ADPKD registry. STUDY DESIG...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderegg, Manuel A., Dhayat, Nasser A., Sommer, Grit, Semmo, Mariam, Huynh-Do, Uyen, Vogt, Bruno, Fuster, Daniel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487949/
https://www.ncbi.nlm.nih.gov/pubmed/32964204
http://dx.doi.org/10.1016/j.xkme.2019.11.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487949/
https://www.ncbi.nlm.nih.gov/pubmed/32964204
http://dx.doi.org/10.1016/j.xkme.2019.11.008

Ejemplares similares